Recent update on fixed combinations of antihypertensive agents

Korean Circulation Journal

Volumn 38, Issue 5, 2008, Pages 237-243

  Chang, Gyu Park ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Amlodipine; Atorvastatin; Combination drug therapy; Risk reduction

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; AVALIDE HCT; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BENICAR HCT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; CHOLESTEROL; DIHYDRALAZINE PLUS HYDROCHLOROTHIAZIDE PLUS RESERPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; FOSINOPRIL; FOSINOPRIL PLUS HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS METHYLDOPA; HYDROCHLOROTHIAZIDE PLUS MOEXIPRIL; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; HYDROCHLOROTHIAZIDE PLUS QUINAPRIL; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MICARDIS HCT; MOEXIPRIL; MONOPHIL HCT; PLACEBO; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; UNIPRES;

ABDOMINAL PAIN; ANKLE EDEMA; ASTHENIA; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COLD EXTREMITY; COST EFFECTIVENESS ANALYSIS; COUGHING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATIGUE; HEADACHE; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMPOTENCE; LIPID BLOOD LEVEL; LOW DRUG DOSE; MONOTHERAPY; MUSCLE CRAMP; MYALGIA; NAUSEA; PATIENT; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRESCRIPTION; PROGNOSIS; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SINUSITIS; SYSTOLIC BLOOD PRESSURE; TABLET FORMULATION; UNSPECIFIED SIDE EFFECT; VASODILATATION;

EID: 47149115484     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2008.38.5.237     Document Type: Review

References (25)

1. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens 2000; 14: 83-90.
2. Health Survey for England 1998. Available at http://www.archive. official-documents.co.uk/document/doh/survey98/hse-00.htm.
3. Asmar R, Vol S, Pannier B, Brisac AM, Tichet J, El Hasnaoui A. High blood pressure and associated cardiovascular risk factors in France. J Hypertens 2001; 19: 1727-32.
4. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165: 1147-52.
5. Agarwal S, McLaughlin T, Joyce A, Schwartz S, Tang S. Synchronizing antihypertensive and lipid-lowering therapies increases patient adherence. J Clin Hypertens 2006; 8 (Suppl A5): A214 (P-519). Abstract.
6. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9 (Suppl): 2-6.
7. Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff 2005; Suppl Web Exclusives: W5-152-W5-66.
8. Lee YS, Kim KS. The short-term effect of atorvastatin on flow-mediated vasodilation, pulse wave velocity and carotid intima-media thickness inpatients with moderate cholesterolemia. Korean Circ J 2008; 38: 144-51.
9. Blank R, LaSalle J, Reeves R, Maroni J, Tarasenko L, Sun F. Single pill therapy in the treatment of concomitant hypertension and dyslipidemia (the Amlodipine/Atorvastatin Gemini Study). J Clin Hypertens 2005; 7: 264-73.
10. Chung M, Calcagni A, Glue P, Bramson C. Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol 2006; 46: 1212-6.
11. Chun KJ, Chung NS, Ha JW, et al. Efficacy and safety of atorvastatin in patients with elevated LDL-cholesterolemia. Korean Circ J 1999; 29: 1309-16.
12. Fogari R, Derosa G, Lazzari P, et al. Effect of amlodipine- atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am J Hypertens 2004; 17: 823-7.
13. Preston RA, Sun F, Tarasenko L. Safety and tolerability of co-administered amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia in the Respond study. Am J Hypertens 2005; 18: A92-3. Abstract.
14. Materson BJ, Reda DJ, Cushman WC. Department of veterans Affairs single-drug therapy of hypertension study: revised figures and new data. Am J Hypertens 1995; 8: 189-92.
15. Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 2001; 14: 241-7.
16. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.
17. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
18. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
19. st ed. Philadelphia: Mosby Elsevier; 2007. p.1061-5.
20. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-9.
21. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427.
22. Bobrie G, Delonca J, Moulin C, et al. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens 2005; 18: 1482-8.
23. Flack JM. Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide. Int J Clin Pract 2007; 61: 2093-102.
24. Ruilope LM, Malacco E, Khder Y, Kandra A, Bonner G, Heintz D. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors. Clin Ther 2005; 27: 578-87.
25. Andreadis EA, Tsourous GI, Marakomichelakis GE, et al. High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. J Hum Hypertens 2005; 19: 491-6.